The Post-Finasteride Syndrome Foundation (PFS Foundation) will be funding another major clinical study at Baylor College of Medicine (BCM) in Houston, Texas. The title of this study is “Genetic and Epigenetic Studies on Post-Finasteride Syndrome Patients.”
Assistant Professor of Urology Dr. Mohit Khera from the Scott Department of Urology (who is also the Director of the Laboratory for Andrology Research, McNair Medical Institute at BCM) will be leading the second major study on the Post-Finasteride Syndrome. Dr. Khera specializes in andrology, sexual wellness, and male reproductive medicine.
Objectives of the Study:
The primary aim of the study is to determine the pathogenic mechanism behind sexual dysfunction in the patients consuming Finasteride for the treatment of prostate cancer (under the brand name Proscar and generics) or management of hair loss (Propecia and generics).
What is Post-Finasteride Syndrome?
The symptomatology varies from patient to patient and according to the dose ingested; however, most commonly reported symptoms are loss of libido, Peyronie’s disease, impairment of cognitive functions, severely dry skin, penile shrinkage, erectile dysfunction, gynecomastia, muscle atrophy, and depression. In addition, research conducted by scientists at University of Texas Health Science Center also suggested that the risk of high grade cancer also increases in patients consuming Finasteride as compared to the placebo.
All these symptoms significantly affect the quality of life (by affecting sexual life, quality of relationships, and financial issues due to loss of job).
The first funding by the PFS Foundation was initiated on July 1st, 2013 that was mainly focused at studying the primary symptomatology at Brigham and Women’s Hospital (BWH) in Boston. BWH is a reputable institute and affiliated with Harvard Medical School teaching unit. In the first study, scientists primarily identify the molecular patho-physiology of the PFS.
The CEO of the PFS Foundation, Dr. John Santmann expressed his views in these words:
“Coupled with the Brigham and Women’s Hospital study, the Baylor research promises to pave the way for PFS therapies by uncovering the root causes of this condition that is likely affecting thousands of men worldwide.”
Background of the study:
Due to reliable reports and mounting evidence, Merck, the drug manufacturer, was advised by the Food and Drug Administration to revise the labeling on Propecia back in April 11, 2012. This action reflected the significant statistical evidence that consumption of Propecia can lead to persistent sexual dysfunction. FDA reviewed over 421 sexual dysfunction cases associated with the use of Propecia-and identified that almost 14% patients reported sexual dysfunction even after three months of quitting the drug.
It is expected that more promising results will be revealed with the research conducted by Baylor College scientists to understand the effects of Finasteride on the human body.